Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

not met at the highest dose evaluated as monotherapy (1000 mg). - No evidence of altered cardiac activity was observed. - Majority of adverse events were mild and mainly occurred during the loading doses. Adverse events consisted of chills, itching and fatigue in over a third of patients. - There was a trend for increasing incidence of some mild adverse events with escalating OGX-427 doses. For example, 33% of patients at the 200-mg dose compared to 67% of patients at the 1000-mg dose had mild adverse events during the loading doses. - The half-life of OGX-427 in the blood remained constant, although there appeared to be an increase in maximum blood levels and a corresponding decease in blood clearance of OGX-427 as doses were escalated.

The combination of 800 mg OGX-427 with docetaxel was also well tolerated and escalation to 1000 mg OGX-427 with docetaxel will be evaluated next.

Circulating Tumor Cell and Tumor Marker Results

Circulating tumor cells (CTCs), an emerging metric to assess treatment effect, was evaluated at baseline before treatment and during treatment. Both total and Hsp27-positive CTCs were evaluated. Declines of 50% or greater in both total and Hsp27-positive CTCs were observed in over half of the patients in each cohort and in each cancer category. Declines in Hsp27 CTCs to 5 or less cells occurred in 27% of patients who had greater than 5 CTCs at baseline.

Reduction in tumor markers defined as declines of PSA levels in prostate cancer or CA-125 levels in ovarian cancer were also observed. A reduction in PSA level was observed in 7 of 20 patients (35%) with prostate cancer and a reduction in CA-125 levels was observed in 3 of 5 patients (60%) with ovarian cancer.

"CTCs are emerging as an exciting surrogate of anti-cancer activity. The frequent decreases in total
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...RNewswire-FirstCall/ -- WaferGen Biosystems, Inc. ... state-of-the-art genetic analysis systems, today ... the company,s Scientific Advisory Board. His car...ing novel molecular diagnostics for cancer detecti...of computational biology systems for several biote...
(Date:11/5/2009)...Surgery and vision correction experts listed in th...nvolved at the recently concluded American Academy... Francisco, California. Dr. Stephen Brint, MD, Dr.... MD, Dr. Peter Rapoza, MD, Dr. Michael Raizman, MD... Dr. Edward Manche, MD, and Dr. Parag Majmudar, MD...
(Date:11/4/2009)...PRNewswire/ -- DIATHERIX Laboratories, Inc. (DIATH...the Michigan Security Network Homeland Security Ma...is Grimaud, Chairman and Chief Executive Officer o... advanced molecular diagnostic testing on bio-prep...agnosis and military efforts. ,, "This confere...
(Date:11/4/2009)... Nektar Therapeutics (Na... for the third quarter ended September 30, 2009. ... 2009 improved to $31.0 million or $0.33 per share....40 per share in the third quarter of 2008. ,...erating efficiencies as compared to a year ago. T...
Breaking Biology Technology:WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 2WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 4Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 2Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 3Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 4Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 5Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 6Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 7Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 8Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 9DIATHERIX Laboratories Presents at Homeland Security Conference 2Nektar Therapeutics Reports Third Quarter 2009 Financial Results 2Nektar Therapeutics Reports Third Quarter 2009 Financial Results 3Nektar Therapeutics Reports Third Quarter 2009 Financial Results 4Nektar Therapeutics Reports Third Quarter 2009 Financial Results 5Nektar Therapeutics Reports Third Quarter 2009 Financial Results 6Nektar Therapeutics Reports Third Quarter 2009 Financial Results 7Nektar Therapeutics Reports Third Quarter 2009 Financial Results 8Nektar Therapeutics Reports Third Quarter 2009 Financial Results 9Nektar Therapeutics Reports Third Quarter 2009 Financial Results 10
... York, December 1, 2008 Although naturally occurr...ern that bioterrorists might obtain smallpox from ...nder such circumstances, the supply of smallpox va...tion. In a study published in the December 2008 is...hers found that lifetime protection is obtained fr...
...EENBELT, Md. - Engineers at the University of Idah...e used in upcoming NASA missions that will study t...eneral guidance of a grant technical officer Pen-S...Flight Center, Greenbelt, Md., the engineering tea...for Advanced Microelectronics Biomolecular Researc...
...BRIDGE, Mass. -- A new type of highly sensitive mi...rsity could greatly expand the limits of modern bi... location of minuscule metabolites and drugs in li... of fluorescent labeling. , The technique, based ...ecting the vibrations in chemical bonds between at...
Other Biology Technology:New study indicates smallpox vaccination effective for decades 2New one-of-a-kind technology will fly on 2 NASA missions 2New one-of-a-kind technology will fly on 2 NASA missions 3New label-free method tracks molecules and drugs in live cells 2
(Date:11/3/2009)...ov. 3, 2009) -- A painstaking analysis of thousand... human beings are biologically complex, at least i...with redundancies arising from duplicate genes. ,... to account for a portion of the intricate biologi...ez, professor of bioengineering at Rice University...
(Date:11/3/2009)...n rhythm is like an orchestra the united expressi...hemical may serve as the conductor, or at least as...(H 2 O 2 ), the active ingredient in color safe bl...ide may act as a signal for the active and resting...ogists suggests. , A study published in the jour...
(Date:11/2/2009)...HARBOR, N.Y. (Mon., Nov. 2, 2009) -- The introduc...atly increased the pace of research into the genet... on one or a few coding variants in a small sample...iciently genotype many individuals and to cover mo...sulted in genetic studies with greater statistical...
Breaking Biology News(10 mins):Study sheds light on evolution of human complexity 2Study sheds light on evolution of human complexity 3Not just bleach: Hydrogen peroxide may tell time for living cells 2Not just bleach: Hydrogen peroxide may tell time for living cells 3High-throughput genotyping, protein purification featured in Cold Spring Harbor Protocols 2Pain Medicine Experts Recommend Safe and Responsible Use of Acetaminophen 50666 1Pain Medicine Experts Recommend Safe and Responsible Use of Acetaminophen 50666 2Partnership for Prescription Assistance Prepared to Help North Dakota Workers Hurt by Recession 50664 1Partnership for Prescription Assistance Prepared to Help North Dakota Workers Hurt by Recession 50664 2Partnership for Prescription Assistance Prepared to Help North Dakota Workers Hurt by Recession 50664 3Partnership for Prescription Assistance Prepared to Help North Dakota Workers Hurt by Recession 50664 4If 2 Painkillers Are Banned What Next 3F 50662 1If 2 Painkillers Are Banned What Next 3F 50662 2If 2 Painkillers Are Banned What Next 3F 50662 3If 2 Painkillers Are Banned What Next 3F 50662 4
...n, the immune system, to battle cancer" In princip...ases: immunization. The production of a selective ... by Horst Kunst at the University of Mainz has now...r tumors to a carrier protein without irritating t...gewandte Chemie, their method is based on an immun...
...bia are studying the status of black bears in Miss...g the 18th and 19th centuries, but have been consi...th century. The results of the MU study will be us...elp manage Missouri’s black bear population. , The...d chemistry major, and Lori Eggert, assistant prof...
...nvolves "pulling all-nighters", or a single night ...with lower grade-point averages compared to those ...bstract that will be presented Wednesday at SLEEP ...ofessional Sleep Societies (APSS). , "Sleep in col...nd of poor quality. As sleep quality and quantity...
Other Biology News:Progress toward an antitumor vaccine 2MU researchers to study the status of black bears in Missouri 2
...JASCO offers a dedicated system for SFC and SFE ap...f HPLC instrumentation. JASCO has recently added t...the system: ,- The PU-1580-CO2 delivery pump for s...rocedures using carbon dioxide as the mobile phase...
Mouse Complement from Equitech-Bio
CERTOMAT U from Sartorius AG
...SpliceArray is a new generation of microarrays to ... enables you to rapidly elucidate alternatively sp... for drug discovery. The service combines ExonHits...e design and customized analysis with Agilents rob...
Biology Products: